Ophtalmic Retino-protective and vector for other molecules final dosages based on the association of sildenafil and bevacizumab.

Abstract

The invention focuses on developing final ophthalmic dosages based on Sildenafil associated with bevacizumab, known for its retino-protective properties, aimed to preserve and improve visual functions, particularly in patients with retinal degenerative disease specially for the dry form of macular degeneration